Artiva Biotherapeutics, Inc. (ARTV) - Dilution Analysis

Visualizing historical and potential share dilution over time

View Stock Details

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Dilution Analysis

Medium Risk

Moderate dilution risk

Last updated: May 08, 2026

Risk Assessment Details

Potential Dilution: 27.82% of current shares

Recent Dilution: 1.85% (2 years)

Historical Dilution Factor: minimal recent dilution

Outstanding Shares

25M

Potential Supply

6.9M

Additional shares possible

Splits

None

Past 2 years

Summary

ARTV currently has 24.7M outstanding shares. with moderate dilution risk from 6.86M authorized shares representing 27.8% potential dilution. The company has minimally diluted shareholders by 1.85% over the past 2 years.

Share Structure Timeline

Outstanding Shares

Total Supply

Historical Data Points

Date	Event	Outstanding	Supply
May 08, 2026	10-Q filing \| 24.7M shares outstanding	25M	6.9M
Mar 10, 2026	10-K filing \| 24.4M shares outstanding	24M	6.9M
Nov 12, 2025	10-Q filing \| 24.5M shares outstanding	24M	6.9M
Aug 06, 2025	10-Q filing \| 24.4M shares outstanding	24M	6.9M
May 08, 2025	10-Q filing \| 24.3M shares outstanding	24M	6.9M
Mar 24, 2025	10-K filing \| 24.4M shares outstanding	24M	6.9M
Nov 12, 2024	10-Q filing \| 24.3M shares outstanding	24M	6.9M
Aug 29, 2024	10-Q filing \| 24.3M shares outstanding	24M	6.9M
Jul 15, 2024	S-1/A filing: This S-1/A filing relates to a company registering shares of common stock for an initial public offering. It details representations, warranties, and agreements between the company and the underwriters, including terms for purchasing and selling firm shares and optional shares, compliance with securities laws, and indemnification.	N/A	6.9M
Jun 28, 2024	S-1 filing: This filing details recent sales of unregistered securities, including Series A and B convertible preferred stock, simple agreements for future equity, stock options, and restricted stock units.	N/A	6.9M
Mar 07, 2022	S-1/A filing: This is an S-1/A filing. It discusses the terms of Series A and Series B convertible preferred stock, including dividends, liquidation preferences, and conversion rights. In February 2021, the company completed a Series B convertible preferred stock financing issuing 10,909,091 shares at a price of $11.00 per share resulting in gross proceeds of $120.0 million.	N/A	0
Apr 08, 2021	S-1 filing: This S-1 filing discusses the market value of shares that have not vested, Series A convertible preferred stock, dividends, preferences on liquidation, conversion rights, and redemption rights.	N/A	0

Back to ARTV Details